SARS CoV 2 News and Research

RSS

Survey finds 41% of United States residents unwilling to receive a COVID-19 vaccine

A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine

3 Feb 2021

Nasodine antiseptic nasal spray shows potential antiviral activity against SARS-CoV-2

A team of international scientists has recently investigated the efficacy of PVP-1, a complex of polyvinylpyrrolidone and iodine, in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Using in vitro cell culture settings, the scientists observe that PVP-1 formulation used in a commercially available nasal spray (Nasodine) readily inactivates SARS-CoV-2 within a short period of time.

3 Feb 2021

Insight into role of aging in response to SARS-CoV-2 infection

Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.

3 Feb 2021

COVID-19 vaccine should be recommended to patients with Parkinson’s disease, experts say

Patients with Parkinson's disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine's efficacy and safety in the specific context of PD and its symptomatic treatment.

3 Feb 2021

How well do fabric face masks protect from COVID?

In a new study, published on the pre-print server medRxiv, researchers at the University of Cambridge found that fabric face masks block 62.6 percent to 87.1 percent of fine particles, making them useful tools in the battle against the COVID-19 pandemic.

3 Feb 2021

Clinical trials of new treatments for COVID-19 often do not include vulnerable populations

Studies examining the effectiveness of treatments for COVID-19 often do not include the very populations hardest hit by the disease, according to a new review by University of Chicago Medicine researchers.

3 Feb 2021

Latest clinical trial supports UK’s decision to delay second COVID vaccine dose

Researchers in the UK, South Africa and Brazil have reported the latest efficacy results from phase III trials of the Oxford–AstraZeneca vaccine currently being rolled out in the UK to protect against coronavirus disease 2019 (COVID-19).

3 Feb 2021

Viral load the main driver of SARS-CoV-2 transmission

A study conducted by researchers in the UK and Spain suggests that viral load is the main determinant of transmission risk in cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

3 Feb 2021

Experimental intranasal influenza vaccine produces durable immune response

An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation.

3 Feb 2021

Could rapid result low sensitivity SARS-CoV-2 tests improve pandemic quarantine strategies?

Researchers in the USA have re-examined current testing and quarantining regimens for SARS-CoV-2. They suggest that the RT-PCR method and 14-day isolation rule may not be the most effective approach in managing viral transmission.

3 Feb 2021

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

Researchers at Chicago University have developed an innovative new anti-SARS-CoV-2 therapy called “Nanotraps” – a family of nano-enabled virus-trapping particles – which have shown positive results in vitro, in vivo, and in human ex vivo trials.

3 Feb 2021

SPT Labtech Announces a Co-Marketing Initiative with Thermo Fisher Scientific to Help Reduce the Cost of NGS Library Prep

Initiative to promote the benefit of using Thermo Fisher Scientific’s library prep kits with SPT Labtech’s instruments to help reduce reagent and material requirements for high-throughput genome sequencing.

From SPT Labtech 3 Feb 2021

Researchers survey repurposed drugs that inhibit SARS-CoV-2 replication in vitro

A new study by researchers at the University of Manchester, UK, reports on the compounds of interest that were identified as having potential for the treatment of COVID-19, from a library of almost 2,000 compounds from the APExBIO DiscoveryProbe library.

3 Feb 2021

Genomic study suggests SARS-CoV-2 clade 20C was imported into Japan from the US

A new study describes the outcome of such sequencing efforts in Japan as an important tool towards containing the spread of the infection.

3 Feb 2021

Long COVID-19 symptoms not associated with reduced cell-mediated immunity, finds study

A new preprint examines Long COVID-19, aiming to identify the underlying immunologic status in such patients.

3 Feb 2021

Oxysterol derivatives show powerful antiviral activity against SARS-CoV-2 in vitro

A new study describes the antiviral activity of oxysterols, or oxidized cholesterol derivatives, against SARS-CoV-2. These occur in nature, and are not only involved in lipid signaling pathways that modulate a host of processes within the body, including the immune response and lipid homeostasis.

3 Feb 2021

Study finds higher pediatric SARS-CoV-2 burden than previously reported in the U.S.

In a new study, published on the pre-print server medRxiv*, researchers at Inova Children's Hospital and the George Mason University revealed that a much higher burden of SARS-CoV-2 infection was found in children than previously reported. This comes after the researchers assessed seropositivity among 1,038 children and adolescents.

3 Feb 2021

Novel strategy redirects generic antibodies to SARS-CoV-2 spike proteins

The SARS-CoV-2, the new coronavirus behind the current pandemic, infects humans by binding its surface-exposed spike proteins to ACE2 receptors exposed on the cell membranes.

3 Feb 2021

Key variants help explain the differences between viruses that cause COVID-19 and SARS

An effort led by Lin Li, Ph.D., assistant professor of physics at The University of Texas at El Paso, in collaboration with students and faculty from Howard University, has identified key variants that help explain the differences between the viruses that cause COVID-19 and Severe Acute Respiratory Syndrome (SARS).

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

SARS CoV 2 News and Research

Survey finds 41% of United States residents unwilling to receive a COVID-19 vaccine

Nasodine antiseptic nasal spray shows potential antiviral activity against SARS-CoV-2

Insight into role of aging in response to SARS-CoV-2 infection

COVID-19 vaccine should be recommended to patients with Parkinson’s disease, experts say

How well do fabric face masks protect from COVID?

Clinical trials of new treatments for COVID-19 often do not include vulnerable populations

Latest clinical trial supports UK’s decision to delay second COVID vaccine dose

Viral load the main driver of SARS-CoV-2 transmission

Experimental intranasal influenza vaccine produces durable immune response

Could rapid result low sensitivity SARS-CoV-2 tests improve pandemic quarantine strategies?

Researchers engineer "Nanotraps" that block SARS-CoV-2 infection

SPT Labtech Announces a Co-Marketing Initiative with Thermo Fisher Scientific to Help Reduce the Cost of NGS Library Prep

Researchers survey repurposed drugs that inhibit SARS-CoV-2 replication in vitro

Genomic study suggests SARS-CoV-2 clade 20C was imported into Japan from the US

Long COVID-19 symptoms not associated with reduced cell-mediated immunity, finds study

Oxysterol derivatives show powerful antiviral activity against SARS-CoV-2 in vitro

Study finds higher pediatric SARS-CoV-2 burden than previously reported in the U.S.

Novel strategy redirects generic antibodies to SARS-CoV-2 spike proteins

Key variants help explain the differences between viruses that cause COVID-19 and SARS

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News